Is CORONA Remedies a Good Buy After Its Q1 FY27 Results?

September 9, 2026
Posted by: Harsh Piplani
Category: Market

CORONA Remedies share price around Rs 2,197. 3.2% below 52-week high of Rs 2,270. Q1 FY27 revenue Rs 426 crore, up 22.1% YoY. PAT Rs 60 crore, up 30.1%. PE 64x.

Quick Answer

CORONA Remedies’ Q1 FY27 results were strong, with revenue at Rs 426 crore and PAT climbing 30% to Rs 60 crore. The stock trades at a PE of 64x against an industry average near 38x, so some of this good news is already priced in. The CORONA Remedies share price near Rs 2,197 reflects that optimism, so investors weighing whether CORONA Remedies is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.

The CORONA Remedies share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. CORONA Remedies is a pharmaceutical company manufacturing formulations across multiple therapeutic areas, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 426 crore, up 22.1% year on year, while profit after tax came in at Rs 60 crore, up 30.1% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the CORONA Remedies share price from here.

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the CORONA Remedies share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Table of Contents

CORONA Remedies Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 426 crore	Rs 349 crore	22.1%
EBITDA	Rs 96 crore	Rs 72 crore	34.1%
Operating Margin	22.8%	20.7%	NA
Profit Before Tax	Rs 80 crore	Rs 61 crore	32.4%
Net Profit / (Loss)	Rs 60 crore	Rs 46 crore	30.1%

CORONA Remedies Q1 FY27 Performance Analysis

Check CORONA Remedies Fundamentals on Univest Screener

Revenue growth of 22.1% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the pharmaceutical formulations manufacturing sector.

The bigger story is on profitability. PAT grew 30% to Rs 60 crore, comfortably ahead of revenue growth, which points to margin expansion or a favourable base effect. This is the kind of quarter that supports the premium the CORONA Remedies share price already commands, though investors should check whether the growth is repeatable or was helped by one-off factors.

On a sequential basis, revenue moved up 19.1% sequentially from Rs 357 crore in the March 2026 quarter and net profit moved up 32.6% sequentially from Rs 45 crore in the prior quarter, giving a fuller picture of the trend behind the CORONA Remedies share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

CORONA Remedies’ revenue grew 22.1% year on year this quarter, taking the quarterly base to Rs 426 crore in a pharmaceutical formulations manufacturing business that remains sensitive to demand and pricing cycles that ultimately feed through to the CORONA Remedies share price.

Margin Movement

EBITDA rose 34.1% to Rs 96 crore, and operating margin moved to 22.8% from 20.7% a year earlier, a sign that cost control or pricing held up during the quarter.

Balance Sheet Position

CORONA Remedies carries a low debt-to-equity ratio of 0.22, giving it a conservative balance sheet heading into the rest of FY27.

Valuation Context

The stock trades at a PE of 64.1x against an industry average of 38.0x, a premium that this quarter’s results will need to justify going forward.

Dividend Details

No interim dividend was declared alongside CORONA Remedies’ Q1 FY27 results. The stock currently carries a trailing dividend yield of 0.48%, based on dividends paid over the last year. Investors tracking the CORONA Remedies share price for income should watch the company’s announcements around its next annual results for any dividend decision.

CORONA Remedies Share Price Outlook for FY27

The Q1 FY27 print sets a reasonably high bar for the rest of the year. If CORONA Remedies can sustain this pace of revenue and profit growth, the current valuation gets easier to justify. The main swing factor is whether this quarter’s momentum reflects a durable trend or a favourable one-off, something the next two quarters should clarify.

For the CORONA Remedies share price to hold its current premium through FY27, the company will likely need to keep posting growth at or near this quarter’s pace, since any slowdown would put pressure on a stock priced for continued strength.

CORONA Remedies Stock Performance

Download the Univest iOS App or Univest Android App to track CORONA Remedies’ live share price and get daily stock updates.

The CORONA Remedies share price was trading around Rs 2,197 as results season played out in late August 2026, roughly 3.2% below its 52-week high of Rs 2,270 and well above its 52-week low of Rs 1,337. Promoter holding stood at 69.0% as of the June 2026 quarter.

The CORONA Remedies share price has room to re-rate further if the growth shown this quarter continues, though much of the good news may already be reflected in the stock near current levels. On profitability ratios, the company reports a return on equity of 24.79% and a book value of around Rs 122 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Valuation Risk

At 64.1x earnings against an industry average of 38.0x, the stock leaves little room for disappointment if growth slows.

Sector and Demand Risk

As a pharmaceutical formulations manufacturing business, CORONA Remedies’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the CORONA Remedies share price well before the next result.

Execution Risk

Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

CORONA Remedies’ Q1 FY27 results were genuinely strong, with revenue at Rs 426 crore and PAT up 30% to Rs 60 crore. That said, at a PE of 64.1x, the CORONA Remedies share price is not inexpensive, so this looks like a quality business trading at a full price rather than a bargain. Existing investors have little to worry about from this print, while new investors asking whether CORONA Remedies is a good buy should weigh the strong quarter against the valuation before adding at current levels.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on CORONA Remedies Q1 FY27 Results

What were CORONA Remedies’ Q1 FY27 results?

Ans. CORONA Remedies reported Q1 FY27 revenue of Rs 426 crore, up 22.1% year on year, and PAT of Rs 60 crore, up 30.1% year on year.

Is CORONA Remedies a good buy after its Q1 FY27 results?

Ans. CORONA Remedies’ core numbers improved this quarter, though at a PE of 64.1x the stock is not inexpensive, so this suits investors comfortable paying up for quality. Investors should form their own view based on their own risk appetite and time horizon.

What is the CORONA Remedies share price today?

Ans. The CORONA Remedies share price was trading around Rs 2,197 in late August 2026, about 3.2% below its 52-week high of Rs 2,270 and well above its 52-week low of Rs 1,337.

What is CORONA Remedies’ revenue and profit for Q1 FY27?

Ans. CORONA Remedies reported revenue of Rs 426 crore and a net profit of Rs 60 crore for the quarter ended June 30, 2026.

Did CORONA Remedies declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside CORONA Remedies’ Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.

What is CORONA Remedies’ PE ratio and is it expensive?

Ans. The CORONA Remedies share price trades at a trailing PE of 64.1x, against an industry average of 38.0x. Investors should compare this with the company’s growth rate before judging value.

What are the key risks for CORONA Remedies investors right now?

Ans. At 64.1x earnings against an industry average of 38.0x, the stock leaves little room for disappointment if growth slows. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is CORONA Remedies’ promoter shareholding?

Ans. Promoter holding in CORONA Remedies stood at 69.0% as of the June 2026 quarter.

Author: Harsh Piplani

I am Harsh Piplani, an Assistant Content Manager with over 5 years of experience in crafting impactful, result-driven content. I hold a B.Com (Hons) degree and have worked across diverse industries, including education, fintech, healthcare, jewellery, and more. I specialise in content strategy, SEO, and optimisation, ensuring that every piece I create is not just well-written but also well-ranked. I believe content should do more than fill space so as to drive traffic, build authority, and support business growth. I enjoy turning complex ideas into clear, engaging narratives, and, as I like to say, I know how to spin words like a web to influence, structured, strategic, and impossible to ignore. For me, great content sits at the intersection of creativity and performance.